Table 10. Survival analysis of patients with GRB7 membrane-associated staining in ovarian cancer.
| A | # of + cores | # of events | Median survival | Mean survival | Log-rank test p-value | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total | Event | Censored | Censor % | Estimate | Lower 95% CI | Upper 95% CI | Mean | SD | |||
| RFS | 0 | 142 | 102 | 40 | 28.17 | 630.00 | 540.00 | 892.00 | 2107.84 | 254.49 | 0.1709 |
| ≥1 | 31 | 17 | 14 | 45.16 | 797.00 | 533.00 | . | 702.52 | 67.39 | ||
| all | 173 | 119 | 54 | 31.21 | 648 | 575 | 947 | 2323.23 | 239.99 | ||
| OS | 0 | 142 | 80 | 62 | 43.66 | 1616.00 | 1292.00 | 2223.00 | 3259.43 | 485.98 | 0.1952 |
| ≥1 | 31 | 12 | 19 | 61.29 | 2554.00 | 1570.00 | . | 1870.68 | 172.65 | ||
| all | 173 | 92 | 81 | 46.82 | 1758.00 | 1411.00 | 2299.00 | 3427.58 | 492.31 | ||
| B | # of + cores | # of events | Median survival | Mean survival | Log-rank test p-value | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total | Event | Censored | Censor % | Estimate | Lower 95% CI | Upper 95% CI | Mean | SD | |||
| RFS | <2 | 160 | 114 | 46 | 28.75 | 619.00 | 540.00 | 797.00 | 2166.89 | 241.00 | 0.0373 |
| ≥2 | 13 | 5 | 8 | 61.54 | 570.00 | 850.69 | 95.47 | ||||
| all | 173 | 119 | 54 | 31.21 | 648 | 575 | 947 | 2323.23 | 239.99 | ||
| OS | <2 | 160 | 88 | 72 | 45 | 1719.00 | 1330.00 | 2223.00 | 3310.74 | 479.76 | 0.2217 |
| ≥2 | 13 | 4 | 9 | 69.23 | 1036.00 | 935.88 | 89.59 | ||||
| all | 173 | 92 | 81 | 46.82 | 1758.00 | 1411.00 | 2299.00 | 3427.58 | 492.31 | ||
(A) Membrane staining, when analyzed as no GRB7 staining (0) vs. at least 1 core positive per patient (≥1), had no significant effect on RFS nor OS. (B) Membrane staining, when analyzed as fewer than 2 cores positive for GRB7 staining (<2) vs. at least 2 positive cores per patient (≥2), shows a significant lengthening of the RFS, but not of the OS. p-values given are log-rank test.